利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.02 秒)

    Reagents, methods and systems to suppress pro-inflammatory cytokines
    5.
    发明授权
    Reagents, methods and systems to suppress pro-inflammatory cytokines 有权
    用于抑制促炎细胞因子的试剂，方法和系统

    公开(公告)号：US08399427B2

    公开(公告)日：2013-03-19

    申请号：US13369419

    申请日：2012-02-09

    申请人： Jeffrey C. Marx

    发明人： Jeffrey C. Marx

    IPC分类号： C12N15/11

    CPC分类号： A61K9/0024 ,  A61K47/34

    摘要： The present invention relates to reagents, methods and systems to treat inflammation and pain in a subject using small interfering RNA (siRNA) molecules targeted to either TNFα, IL1, IL6 and other pro-inflammatory cytokines.

    摘要翻译： 本发明涉及使用针对TNFα，IL1，IL6和其它促炎细胞因子的小干扰RNA（siRNA）分子治疗受试者的炎症和疼痛的试剂，方法和系统。

    COMPOSITIONS AND METHODS FOR DELIVERING CLONIDINE TO A TARGET TISSUE SITE
    6.
    发明申请
    COMPOSITIONS AND METHODS FOR DELIVERING CLONIDINE TO A TARGET TISSUE SITE 审中-公开
    组合物和方法将克隆定为目标组织位点

    公开(公告)号：US20120142747A1

    公开(公告)日：2012-06-07

    申请号：US13309759

    申请日：2011-12-02

    申请人： Jared T. Wilsey ,  Danielle L. Biggs ,  Jonathan K. Gray ,  Jeffrey C. Marx ,  William F. McKay ,  Josee Roy ,  John Myers Zanella

    发明人： Jared T. Wilsey ,  Danielle L. Biggs ,  Jonathan K. Gray ,  Jeffrey C. Marx ,  William F. McKay ,  Josee Roy ,  John Myers Zanella

    IPC分类号： A61K31/4168 ,  A61P29/00

    CPC分类号： A61K31/4168 ,  A61K9/00 ,  A61K9/0024

    摘要： Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release clonidine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days or longer.

    摘要翻译： 提供长时间有效的疼痛治疗。 通过在目标部位或其附近施用有效量的立即释放可乐定和持续释放的可乐定，可以减轻由不同来源引起的疼痛，包括但不限于脊椎椎间盘突出症（即坐骨神经痛），脊柱狭窄，狭窄，椎间盘突出 背痛和关节疼痛。 当在可生物降解的聚合物中提供适当的制剂时，这种缓解可以持续至少三天。 在一些实施方案中，缓解可以是至少二十五天，至少五十天，至少一百天，至少一百三十五天或至少一百八十天或更长。

    Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
    7.
    发明授权
    Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use 有权
    包含用于治疗神经元损伤的生物膜密封剂的组合物和使用方法

    公开(公告)号：US08945623B2

    公开(公告)日：2015-02-03

    申请号：US11418152

    申请日：2006-05-03

    申请人： Josee Roy ,  William F. McKay ,  Jeffrey C. Marx

    发明人： Josee Roy ,  William F. McKay ,  Jeffrey C. Marx

    IPC分类号： A61K38/20 ,  A61K38/18 ,  A61K38/11 ,  A61K38/05 ,  A61K31/65 ,  A61K31/56 ,  A61K9/14 ,  A61K9/00 ,  A61K33/06 ,  A61K47/10

    CPC分类号： A61K33/06 ,  A61K9/0019 ,  A61K31/56 ,  A61K31/65 ,  A61K31/765 ,  A61K47/10

    摘要： The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.

    摘要翻译： 本发明提供用于治疗神经元损伤的组合物，试剂盒和方法。 在一个实施方案中，组合物包含生物膜密封剂，例如PEG，以及生物活性剂，例如镁化合物。 静脉内给药，肌内给药，鞘内给药，皮下给药，硬膜外给药，胃肠外给药，直接施用于病理状况的部位或其附近的生物膜密封剂和/或生物活性剂，以及任何 其组合。 或者，生物膜密封剂和/或生物活性剂可以从泵或植入物递送。

    Hygroscopic treatment for degenerating discs
    10.
    发明申请
    Hygroscopic treatment for degenerating discs 审中-公开
    退化光盘的吸湿处理

    公开(公告)号：US20080097229A1

    公开(公告)日：2008-04-24

    申请号：US11511701

    申请日：2006-08-29

    申请人： Josee Roy ,  Susan J. Drapeau ,  Jeffrey C. Marx ,  Sean M. Haddock

    发明人： Josee Roy ,  Susan J. Drapeau ,  Jeffrey C. Marx ,  Sean M. Haddock

    IPC分类号： A61M31/00 ,  B65D69/00

    CPC分类号： A61L27/50 ,  A61F2002/30075 ,  A61F2002/444 ,  A61F2210/0061 ,  A61L27/14 ,  A61L2430/38

    摘要： Early treatment for a degenerated disc includes identifying a non-ruptured, dehydrated disc. A hygroscopic agent is then selected. This agent should pull water towards itself and have a hygroscopic compound with a molecular weight of at least 400 Daltons. Additionally, it may be desirable to selected hygroscopic compounds that are anionic or electrically neutral. The hygroscopic agent is then injected into the nucleus pulposus of the disc without any prior removal of the nucleus pulposus material. Because the surrounding disc structure allows for the passive diffusion of water into the nucleus pulposus, the hygroscopic agent will draw water into the nucleus pulposus, thus promoting tissue hydration within the disc. The hygroscopic agent may also include a biological agent and/or an imaging agent.

    摘要翻译： 退化椎间盘的早期治疗包括鉴定未破裂的脱水椎间盘。 然后选择吸湿剂。 该试剂应将水拉向自身并具有分子量至少为400道尔顿的吸湿性化合物。 另外，可能需要选择阴离子或电中性的吸湿化合物。 然后将吸湿剂注射到盘的髓核中，而无需先前去除髓核成分材料。 因为周围的圆盘结构允许水被钝化地扩散到髓核中，吸湿剂会将水吸入髓核，从而促进椎间盘内的组织水合作用。 吸湿剂还可以包括生物制剂和/或成像剂。